AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Status:
Withdrawn
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This Phase 2, open-label study is designed to examine the efficacy and safety of single-agent
AGEN2034 and combination AGEN2034 + AGEN1884 in patients with recurrent, inoperable or
metastatic Angiosarcoma (AS).